Item 4 — Purpose of Transaction
On January 5, 2026, the Reporting Person and the Azcarraga Trust entered into a transaction agreement (the "Transaction Agreement") with Alfonso de Angoitia Noriega ("AAN") and Bernardo Gomez Martinez ("BGM"), pursuant to which the Reporting Person agreed to sell to AAN 13,166,166,402 A Shares and to BGM 13,166,166,402 A Shares (collectively, the "Acquired Shares"), for an aggregate purchase price of Ps.1,926,303,610. Pursuant to the Transaction Agreement, each of AAN and BGM agreed that following their acquisition of the Acquired Shares, the Reporting Person, through the Azcarraga Trust, will have the right to exercise all voting rights attached to the Acquired Shares, together with 38,580,509 CPOs held by AAN prior to the entry into the Transaction Agreement (the "A Specified CPOs") and 38,699,325 CPOs held by BGM prior to the entry into the Transaction Agreement (the "B Specified CPOs"), with respect to the appointment, removal and/or ratification of members of the Issuer's board of directors ("Special Voting Rights") so long as the Reporting Person is not declared legally dead, incapacitated or absent and holds more than fifty-percent (50%) of the shares in the Azcarraga Trust, other than the Acquired Shares. Each of AAN and BGM will have the right to exercise all voting rights attached to each of their Acquired Shares and the A Specified CPOs and B Specified CPOs, respectively, other than those specified in the preceding sentence. In addition, under the Transaction Agreement, in the event that the Reporting Person, directly or through the Azcarraga Trust, AAN or BGM intend to transfer the Acquired Shares or any other shares of or securities representing the Issuer's capital stock (including CPOs or global depositary shares), the other parties thereto will have a right of first refusal allowing them to purchase such shares or securities at the proposed sale price. The acquisition of the Acquired Shares contemplated by the Transaction Agreement is subject to certain closing conditions, including receipt of required regulatory approval in Mexico. The foregoing summary of the Transaction Agreement does not purport to be complete and is qualified in its entirety by reference to the Transaction Agreement, a copy of which is filed as Exhibit 99.3 to this Amendment No. 3 and incorporated herein by reference.